Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Slideshows|July 4, 2017

Real-World Effectiveness of Antipsychotics

Author(s)Brian Miller, MD, PhD, MPH

Which of these agents best prevents relapse? A recent study employed a novel approach to find out.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Latest CME

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Trending on Psychiatric Times

Psychiatry on Trial: Are Psychiatrists Responsible for Their Patients’ Criminal Behavior?

The 5 Faces of Bipolar Depression: A Case-Based Reflection

Changes in Self-Awareness Following Traumatic Brain Injury: Assessment and Practical Treatment Considerations

Biomarker Testing for Alzheimer Disease: Inside the Latest P-Tau217 Data

Perimenopausal Depression May Signal a Hormonal Component: When to Consider HRT